

Biomarkers Provide Insight into a Patient's Risk Stratification and Potential Response to CLL Therapies



Testing for CLL biomarkers



Is performed at **diagnosis** and **throughout initial and subsequent lines of therapy**, as molecular aberrations may emerge during the disease course¹



Uses a patient's **peripheral blood** or **bone marrow** sample²




Determines whether select biomarkers (eg, **del(17p)/TP53**) are present, which can provide prognostic and/or predictive information^{2,3}

Established biomarkers with prognostic value³

Prognosis	Cytogenetic marker	Molecular marker
Favorable	• del(13q) alone—55% of patients⁴	• Mutated <i>IGHV</i>—60% of patients³
Intermediate	• Trisomy 12—10%-20% of patients⁴ • Normal karyotype³	
Unfavorable	• Del(17p)—5%-8% of patients^{4,a} • Del(11q)—10% of early disease and 25% of advanced disease^{4,a} • Complex karyotype—14%-34% of patients⁵	• <i>TP53</i> mutation—8% of untreated patients³ • Unmutated <i>IGHV</i>—40% of patients³

^aChemotherapy-naïve.

Currently, biomarker testing occurs infrequently outside of major academic centers⁶



Includes testing in both previously untreated and relapsed/refractory patients.

Data from Mato AR, et al.⁶

Awareness and integration of biomarkers into clinical practice is important to improve the diagnosis, prognosis, and treatment of patients with CLL⁶

CLL, chronic lymphocytic leukemia; del(11q), deletions of the long arm of chromosome 11; del(13q), deletions of the long arm of chromosome 13; FISH, fluorescence in situ hybridization; del(17p), deletions of the short arm of chromosome 17; *IGHV*, immunoglobulin heavy chain variable region gene; *TP53*, tumor protein 53.

1. Campo E, et al. *Haematologica*. 2018;103(12):1956-1968. 2. Seymour EK, et al. *Cancer*. 2019;125(1):135-143. 3. Lee J, Wang YL. *J Mol Diagn*. 2020;22(9):1114-1125. 4. Hallek M, Al-Sawaf O. *Am J Hematol*. 2021;96(12):1679-1705. 5. Visentin A, et al. *Haematologica*. 2022;107(4):868-876. 6. Mato AR, et al. *Clin Lymphoma Myeloma Leuk*. 2020;20(3):174-183.e3.

VV-MED-156348 03/2024 © 2024 Lilly USA, LLC. All rights reserved.